C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

por Temesgen, Zelalem, Kelley, Colleen F, Cerasoli, Frank, Kilcoyne, Adrian, Chappell, Dale, Durrant, Cameron, Ahmed, Omar, Chappell, Gabrielle, Catterson, Victoria, Polk, Christopher, Badley, Andrew, Marconi, Vincent C
Publicado 2023

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

por Temesgen, Zelalem, Burger, Charles D., Baker, Jason, Polk, Christopher, Libertin, Claudia, Kelley, Colleen, Marconi, Vincent C., Orenstein, Robert, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D.
Publicado 2021

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL

por TEMESGEN, ZELALEM, BURGER, CHARLES, BAKER, JASON, POLK, CHRISTOPHER, LIBERTIN, CLAUDIA, KELLEY, COLLEEN, MARCONI, VINCENT, ORENSTEIN, ROBERT, CATTERSON, VICTORIA, ARONSTEIN, WILLIAM, DURRANT, CAMERON, CHAPPELL, DALE, CHAPPELL, GABRIELLE, AHMED, OMAR, BADLEY, ANDREW
Publicado 2021

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial

por Temesgem, Zelalem, Burger, Charles, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent, Orenstein, Robert, Catterson, Victoria, Aronstein, William, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew
Publicado 2021

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

por Temesgen, Zelalem, Burger, Charles D, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent C, Orenstein, Robert, Catterson, Victoria M, Aronstein, William S, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D
Publicado 2022

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms

por Reinke, Sören, Pantazi, Eirini, Chappell, Gabrielle R., Sanchez-Martinez, Alexandra, Guyon, Romain, Fergusson, Joannah R., Salman, Ahmed M., Aktar, Anjum, Mukhopadhyay, Ekta, Ventura, Roland A., Auderset, Floriane, Dubois, Patrice M., Collin, Nicolas, Hill, Adrian V.S., Bezbradica, Jelena S., Milicic, Anita
Publicado 2023

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

por Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Publicado 2020